A randomized, controlled Phase 2 trial investigating pegozafermin, a FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH) patients with F2/F3 ﬁbrosis

pegozafermin (BIO89-100) - 89Bio

https://www.cardiometabolichealth.org/18th-annual-cardiometabolic-health-congress-2023-abstracts/

Deepak L Bhatt; Arun J Sanyal; Stephen A Harrison; Millie Gottwald; Shibao Feng; Germaine D Agollah; Cynthia L Hartsfield; Hank Mansbach; Maya Margalit; Rohit Loomba

Nov 1, 2023